% IMPORTANT: The following is UTF-8 encoded. This means that in the presence % of non-ASCII characters, it will not work with BibTeX 0.99 or older. % Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or % “biber”. @ARTICLE{Stokkel:301474, author = {M. P. M. Stokkel and M. Gotthardt and K. Herrmann$^*$ and G. Gnanasegaran}, title = {{T}heranostics in {P}erspective: {W}hite {P}aper.}, journal = {Journal of nuclear medicine}, volume = {66}, number = {7}, issn = {0097-9058}, address = {New York, NY}, publisher = {Soc.}, reportid = {DKFZ-2025-01016}, pages = {1007–1011}, year = {2025}, note = {66(7), pp. 1007–1011}, abstract = {Nuclear medicine has evolved from a diagnostic-oriented speciality toward theranostics. Radionuclide therapy has become a booming business with newer radiopharmaceuticals and indications. Although the specialty of nuclear medicine seems scintillating, several challenges might limit sustained and long-term success. Some of the challenges and issues requiring clarification include radiopharmaceutical cost and supply, cost-benefit analysis, reimbursement, training, workforce, collaboration with the radiopharmaceutical industry, national and international nuclear medicine, and applied specialities. This review discusses these challenges and possible solutions to avoid speed breakers in theranostics.}, subtyp = {Review Article}, keywords = {challenges (Other) / future (Other) / opportunities (Other) / radionuclide therapy (Other) / theranostics (Other)}, cin = {ED01}, ddc = {610}, cid = {I:(DE-He78)ED01-20160331}, pnm = {899 - ohne Topic (POF4-899)}, pid = {G:(DE-HGF)POF4-899}, typ = {PUB:(DE-HGF)16}, pubmed = {pmid:40374556}, doi = {10.2967/jnumed.125.269776}, url = {https://inrepo02.dkfz.de/record/301474}, }